Short interest in VEEV jumped 22% in a single week. The move follows a high-profile analyst downgrade. Options markets are sending a different signal entirely.
SI hit 3.6% of free float as of April 27. That's up from roughly 2.9% a week earlier. The spike was sharp — an 18% single-day jump on April 24 drove much of the move.
The catalyst is visible in the analyst data. Citigroup's Tyler Radke downgraded Veeva from Buy to Neutral on April 10. The price target fell from $291 to $176 — a 40% cut. The consensus mean target now sits at $264, against a current price of $158.49. That's a wide gap, but Citi's cut stands out for its severity.
The stock has responded accordingly. VEEV is down 8.2% over the past month and 5.5% over the past week.
The borrow market has tightened, but not dramatically. Cost to borrow rose to 0.41% as of April 27, up 16% over the week. Availability remains ample — the borrow market is nowhere near stressed territory. Days to cover stands at 2.49, per the latest FINRA data.
The short score edged up to 35.1 from 33.1 over the past two weeks. That's a moderate rise, not an alarm.
Here's the tension: options traders are leaning bullish. The put/call ratio came in at 0.46 on April 28. That's 2.16 standard deviations above the 20-day mean of 0.38 — but the direction matters. A low PCR means more calls than puts. Options positioning is tilted toward upside.
The 52-week PCR range is 0.31 to 0.69. At 0.46, the current reading sits in the lower half — firmly call-heavy.
Shorts are building. Options buyers are buying calls. One side is wrong.
Earnings are due May 27. The last print on March 4 produced a 5.5% one-day gain. EPS momentum scores are constructive — 57th percentile on a 30-day basis, 81st percentile over 90 days.
T. Rowe Price added 469,160 shares in Q1, making it the most active buyer among major institutional holders. BlackRock added 242,740. The insider picture is less encouraging — net insider activity over 90 days was positive in share count terms, but recent trades skew toward routine executive sales at prices well above current levels.
The bear case centres on slowing growth in FY27 and stretched valuation. The bull case rests on Veeva's entrenched position in life sciences software and a consistent earnings track record. With VEEV now trading at a PE of 17.5 and EV/EBITDA of 11.7, valuation has come in sharply. Whether that's enough to absorb the short-side pressure becomes clearer on May 27.
Watch: PCR direction heading into earnings. A rising PCR alongside a continued SI build would signal genuine sentiment deterioration.
See the live data behind this article on ORTEX.
Open VEEV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
